Realizing individualized cancer treatment through patient genome sequencing

Recent Publications

Kawakami, R., Mashima, T., Kawata, N., Kumagai, K., Migita, T., Sano, T., Mizunuma, N., Yamaguchi, K. and Seimiya, H.
ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer.
Cancer Sci., in press (2020)
Takahashi, K., Seto, Y., Okada, K., Uematsu, S., Uchibori, K., Tsukahara, M., Oh-hara, T., Fujita, N., Yanagitani, N., Nishio, M., Okubo, K. and Katayama, R.
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Thorac. Cancer, in press (2020)
Jang, M. K., Mashima, T. and Seimiya, H.
Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase.
Mol. Cancer Ther., in press (2020)
Tanaka, N., Takahara, A., Hagio, T., Nishiko, R., Kanayama, J., Gotoh, O. and Mori, S.
Sequencing artifacts derived from a library preparation method using enzymatic fragmentation.
PLoS One, 15, e0227427 (2020)
Mizutani, A. and Seimiya, H.
Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
Biochem. Biophys. Res. Commun., in press (2019)

more